Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects

To evaluate the safety and efficacy of combining Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC patients. Patients were randomly assigned to the test or control gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaoliang, Su, Yanjun, You, Jian, Gong, Liqun, Zhang, Zhenfa, Wang, Meng, Zhao, Zhenqing, Zhang, Zhen, Li, Xiaolin, Wang, Changli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308751/
https://www.ncbi.nlm.nih.gov/pubmed/27566586
http://dx.doi.org/10.18632/oncotarget.11547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308751/
https://www.ncbi.nlm.nih.gov/pubmed/27566586
http://dx.doi.org/10.18632/oncotarget.11547

Ejemplares similares